These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

66 related items for PubMed ID: 7675451

  • 1. Mutation at tyrosine residue 1337 abrogates ligand-dependent transforming capacity of the FLT4 receptor.
    Fournier E, Dubreuil P, Birnbaum D, Borg JP.
    Oncogene; 1995 Sep 07; 11(5):921-31. PubMed ID: 7675451
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Role of tyrosine residues and protein interaction domains of SHC adaptor in VEGF receptor 3 signaling.
    Fournier E, Blaikie P, Rosnet O, Margolis B, Birnbaum D, Borg JP.
    Oncogene; 1999 Jan 14; 18(2):507-14. PubMed ID: 9927207
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Use of signal specific receptor tyrosine kinase oncoproteins reveals that pathways downstream from Grb2 or Shc are sufficient for cell transformation and metastasis.
    Saucier C, Papavasiliou V, Palazzo A, Naujokas MA, Kremer R, Park M.
    Oncogene; 2002 Mar 14; 21(12):1800-11. PubMed ID: 11896612
    [Abstract] [Full Text] [Related]

  • 6. Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts.
    Pajusola K, Aprelikova O, Armstrong E, Morris S, Alitalo K.
    Oncogene; 1993 Nov 14; 8(11):2931-7. PubMed ID: 7692369
    [Abstract] [Full Text] [Related]

  • 7. Characterization of murine Flt4 ligand/VEGF-C.
    Fitz LJ, Morris JC, Towler P, Long A, Burgess P, Greco R, Wang J, Gassaway R, Nickbarg E, Kovacic S, Ciarletta A, Giannotti J, Finnerty H, Zollner R, Beier DR, Leak LV, Turner KJ, Wood CR.
    Oncogene; 1997 Jul 31; 15(5):613-8. PubMed ID: 9247316
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor.
    Jeffers M, Koochekpour S, Fiscella M, Sathyanarayana BK, Vande Woude GF.
    Oncogene; 1998 Nov 26; 17(21):2691-700. PubMed ID: 9840933
    [Abstract] [Full Text] [Related]

  • 14. The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor.
    Galland F, Karamysheva A, Pebusque MJ, Borg JP, Rottapel R, Dubreuil P, Rosnet O, Birnbaum D.
    Oncogene; 1993 May 26; 8(5):1233-40. PubMed ID: 8386825
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines.
    Pajusola K, Aprelikova O, Korhonen J, Kaipainen A, Pertovaara L, Alitalo R, Alitalo K.
    Cancer Res; 1992 Oct 15; 52(20):5738-43. PubMed ID: 1327515
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The Tek/Tie2 receptor signals through a novel Dok-related docking protein, Dok-R.
    Jones N, Dumont DJ.
    Oncogene; 1998 Sep 03; 17(9):1097-108. PubMed ID: 9764820
    [Abstract] [Full Text] [Related]

  • 20. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase.
    Rodrigues GA, Park M.
    Oncogene; 1994 Jul 03; 9(7):2019-27. PubMed ID: 8208547
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.